Skip to content

Nebulized Versus Intravenous Dexmedetomidine for Sevoflurane Induced Emergence Agitation After Pediatric Tonsillectomy

Nebulized Versus Intravenous Dexmedetomidine for Managing Sevoflurane Induced Emergence Agitation After Pediatric Tonsillectomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05641376
Enrollment
120
Registered
2022-12-07
Start date
2023-02-01
Completion date
2023-12-01
Last updated
2023-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence Agitation

Brief summary

Pediatric patients undergoing tonsillectomy and adenoidectomy usually have a high incidence of postoperative EA, which increases the risk of developing postoperative airway obstruction and respiratory depression due to anatomical characteristics of operative location and increased susceptibility to opioid analgesics. the study will compare between nebulized and intravenous bolus of dexmedetomidine as a prophylaxis against postanesthetic emergence agitation in children undergoing tonsillectomy, adenoidectomy or adeno-tonsillectomy procedures.

Interventions

Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.

Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

* ASA I and II * Children scheduled for tonsillectomy with or without adenoidectomy with or without myringotomy, and/or tympanostomy tube insertion.

Exclusion criteria

* Patient's guardian refusal to participate in the study. * Children with Behavioral changes; physical or developmental delay; neurological disorder or psychological disorder. * Children on sedative or anticonvulsant medication. * history of sleep apnea * significant organ dysfunction, cardiac dysrhythmia, congenital heart disease * Known allergy to the study drugs.

Design outcomes

Primary

MeasureTime frameDescription
postoperative Emergence agitation will be evaluated using the Paediatric Anaesthesia Emergence Delirium scale60 minutesPaediatric Anaesthesia Emergence Delirium (PAED) scale will be used to evaluate emergence agitation upon admission to the PACU (0 min, baseline) and at 5, 10, 20, 30, 45, and 60 min until discharge from the PACU. The highest EA scores observed during this period will be recorded. PAED score ≥ 10 will be considered to be a diagnostic endpoint for the development of agitation.

Secondary

MeasureTime frameDescription
Postoperative pain60 minutesPostoperative pain will be recorded using FLACC scale at 5, 10, 20, 30, 45, and 60 min until discharge from the PACU.
emergence agitation (EA) onset60 minutesEmergence agitation onset time was defined as the interval from the extubation to the occurrence.
Emergence Agitation duration60 minutesEmergence agitation duration was the time from Emergence agitation onset to its cessation

Countries

Egypt

Contacts

Primary ContactAhmed A Mohammed, M.D.
ahmedfotoh86@aun.edu.eg01060757593
Backup ContactShimaa A hassan, M.D.
shimaa.abbas@med.aun.edu.eg01002953253

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026